Abstract # 2203 Improving the Therapeutic Ratio of Prostate Brachytherapy: Dose Escalation in I-125 Prostate Implants

Presenter: Kao, Johnny

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

The 5 year bDFS (ASTRO definition) for the entire cohort was 96.6%. The positive biopsy rate was 4.1%. For low risk patients, the 5 year bDFS was 97.1% while for intermediate/high risk patients, the 5 year bDFS was 92.6%. There were no PSA failures beyond 6 years. Freedom from ≥ grade 2 rectal bleeding at 5 years was 88.5%. Acute urinary retention occurred in 10.7%, more commonly in patients with high pretreatment IPSS scores (p<0.01). The median IPSS scores increased significantly during the first six months after implant. The median IPSS was 6 (range 0-28; 25 to 75th percentile: 3-10) pre-implant compared to 6 (range 0-31; 25 to 75th percentile: 3-11) post-implant with 3-year minimum follow-up. Using a 2-tailed t-test with unequal variance, there were no significant differences between pre and post-implant IPSS scores (p=0.14). Among patients who were potent prior to treatment, 73.4% remained potent at 5 years after implant.

Click on images to enlarge (a new pop-up window will open)

ASTRO 2006 Poster:

Abstracts Main Page | Logout